Ximelagatran in prevention of cardiovascular events
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000857
To summarize the available information on the use of ximelagatran (Trade Name: Exanta, manufactured by AstraZeneca) in the prevention of cardiovascular events.
Authors' recomendations: Evidence suggests that ximelagatran is comparable to warfarin in preventing stroke. Phase III secondary prevention trials are needed to further assess the safety and efficacy of this drug in post-myocardial infarction (MI) patients. The bleeding risk appears to be similar to that of warfarin, but when there is bleeding, there is no specific antidote to reverse its anticoagulant effect. The safety of ximelagatran, when used with other drugs such as NSAIDS and statins, must still be evaluated. After marketing, surveillance for liver toxicity will be needed. As the cost of the drug is unknown, its cost-effectiveness is yet to be determined.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Cardiovascular Diseases
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.